Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tie Goes To The Nominee: Becerra Heads To Senate Floor

Executive Summary

Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.

You may also be interested in...



Drug Pricing Among Range Of Issues Senators Want HHS Nominee Becerra To Work On

Senate Finance confirmation hearing concluded without a vote on Xavier Becerra’s nomination as Health and Human Services Department secretary. Republicans continued to express concerns with his background and views. But he is expected to win enough votes to clear the committee.

US Medicare Price Negotiation: Gaming FDA Approval Dates Could Delay Drug Selection

The early February date for publishing the list of products eligible for price negotiations could dictate approval strategies for drugs with potential for big sales in Medicare going forward.

Medicare Part D Redesign Could Expand Rebate-Driven Formulary Exclusions In Program

Increased application of utilization management controls expected as plans face higher costs under the redesign. However, the formulary advantages available to drugs in the protected classes may lead developers to sharpen their focus on those categories.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143889

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel